Dr. Samir N. Khleif, Director of the GRU Cancer Center at Georgia Regents University, has been elected to the Board of Directors of the Society for Immunotherapy of Cancer (SITC), the most prestigious organization in the field of cancer immunology and immunotherapy. He was the only elected candidate representing an American institution.
Members are elected to the 13-member board for three year terms. Dr. Khleif joins Dr. Jerome Galon, Research Director at the French National Institute of Health and Medical Research, Cordeliers Research Center in Paris and Dr. Pamela S. Ohashi, Senior Scientist at the Princess Margaret Cancer Centre at the University of Toronto as a new Board member.
About the Society for Immunotherapy for Cancer
Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a non-profit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, clinicians, health care professionals, government leaders and industry professional around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word “cure” a reality for cancer patients everywhere.
About the GRU Cancer Center
The GRU Cancer Center is a multidisciplinary academic cancer center with a mission to reduce the burden of cancer in Georgia and across the globe through superior care, innovation and education. Its patient-centered approach includes first-in-the-nation treatment protocols, an experimental therapeutics program and specialized clinics for Phase I trials and immunotherapy.